BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 20919830)

  • 1. The potential of immunomodulatory drugs in the treatment of solid tumors.
    Dalgleish A; Galustian C
    Future Oncol; 2010 Sep; 6(9):1479-84. PubMed ID: 20919830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the history, properties, and use of the immunomodulatory compound lenalidomide.
    Zeldis JB; Knight R; Hussein M; Chopra R; Muller G
    Ann N Y Acad Sci; 2011 Mar; 1222():76-82. PubMed ID: 21434945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide mode of action: linking bench and clinical findings.
    Davies F; Baz R
    Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C; Carter T; Schafer P; Chopra R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of lenalidomide in the treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
    Melchert M; Kale V; List A
    Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMiDs: a novel class of immunomodulators.
    Knight R
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
    Raje N; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
    Ladizinski B; Shannon EJ; Sanchez MR; Levis WR
    J Drugs Dermatol; 2010 Jul; 9(7):814-26. PubMed ID: 20677538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
    Komrokji RS; List AF
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
    Ortega J; List A
    Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide: an immunomodulatory drug.
    Crane E; List A
    Future Oncol; 2005 Oct; 1(5):575-83. PubMed ID: 16556034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide in solid tumors.
    Segler A; Tsimberidou AM
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1393-406. PubMed ID: 22584909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide as a novel therapeutic agent: new uses for an old product.
    Teo SK; Stirling DI; Zeldis JB
    Drug Discov Today; 2005 Jan; 10(2):107-14. PubMed ID: 15718159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.